Ger, Tzong-YunTzong-YunGerHuang, Yu-HueiYu-HueiHuangHui, Rosaline Chung-YeeRosaline Chung-YeeHuiTSEN-FANG TSAIHSIEN-YI CHIU2020-10-272020-10-2720192040-6223https://scholars.lib.ntu.edu.tw/handle/123456789/518164Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure. The objective of this study was to investigate the real-world effectiveness and safety of secukinumab therapy and analyze subgroups stratified by reimbursement or prior biologic failure.journal articlebiologic failure; real-world; reimbursement; secukinumab; tumor necrosis factor-α inhibitors; ustekinumab[SDGs]SDG3Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursementjournal article10.1177/204062231984375631024679WOS:000464955600001